NRXS Form 4: Director Grant of 13,157 Shares to Kristin Ferge
Rhea-AI Filing Summary
Kristin Ferge, a director of Neuraxis, Inc. (NRXS), reported a non-derivative acquisition of common stock on 01/17/2025. She acquired 13,157 shares at a price of $2.85 per share. Following this transaction, Ms. Ferge beneficially owned 14,340 shares. The filing states these shares were issued as compensation for services rendered as an independent director of the company. The Form 4 shows the filing is made by one reporting person and includes the reporting person’s address in Carmel, IN.
Positive
- Shares issued as director compensation align the reporting person’s interests with shareholders
- Timely disclosure of the acquisition on Form 4 provides transparency into insider ownership changes
Negative
- None.
Insights
TL;DR: Director received stock compensation, aligning her financial interest with shareholders without indicating material control changes.
This Form 4 documents a routine director compensation grant: 13,157 shares issued as payment for independent director services. Such equity awards are common and serve to align a director’s incentives with shareholder performance. The report shows a modest post-transaction holding of 14,340 shares, suggesting the grant represents a material portion of her reported holdings but does not by itself change governance control or signal a significant shift in insider ownership.
TL;DR: Insider acquisition via compensation is a neutral disclosure; transaction size appears routine for director pay.
The transaction is recorded as an acquisition at $2.85 per share on 01/17/2025, with shares issued rather than purchased on the open market. As a compensation issuance, this does not reflect a director-initiated market purchase and therefore is less indicative of a personal investment conviction. The disclosure is timely and provides transparency on changes in beneficial ownership.